dihexa is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
He continued updating this publication to 2010, and it with its research documents and notes, including about half a million press cuttings, is now archived at the Bishopsgate Institute. William Rothenstein (29 January 1872 – 14 February 1945), painter, printmaker, draughtsman, lecturer, writer on art; wrote several critical books and pamphlets, including Goya; the first English monograph on the artist), A Plea for a Wider Use of Artists & Craftsmen and Whither Painting; published three volumes of memoirs: Men and Memories, Vol I and II and Since Fifty. Men and Memories Volume I includes anecdotes about Oscar Wilde and many other friends of Rothenstein's, including Max Beerbohm, James Whistler, Paul Verlaine, Edgar Degas, and John Singer Sargent. Hannah Rothschild (born 22 May 1962), daughter of Jacob Rothschild, 4th Baron Rothschild, author, businesswoman, philanthropist and documentary filmmaker, has written screenplays and journalism, a biography and two novels; serves on charitable and financial boards and is first female to chair the Board of Trustees of the National Gallery in London;liaison trustee for the Tate Gallery;trustee of the Whitechapel Gallery;chair of Yad Hanadiv in Israel; directed films for Saturday Review, Arena and Omnibus; has written for The Times, The New York Times, The Observer, The Guardian, Daily Telegraph, Vanity Fair, Vogue, The Spectator and Harper's Bazaar, Financial Times, Elle, Washington Post and others.
== Theranos == In May 2015, Diamandis performed a deep investigation into claims of health technology company Theranos and concluded in a report that "most of the company's claims are exaggerated." This insight from Diamandis triggered John Carreyrou to further investigate the claims that had been made by Theranos. At the time, Theranos was widely considered a reliable and functional analysis company.
== Chemistry == Tiagabine, also known as (–)-(R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid, is a GABA analogue and a derivative of nipecotic acid. Being a nipecotic acid derivative, introduction of 4,4-diphenylbut-3-enyl and 4,4-bis(3-methylthiophene-1-yl)but-3-enyl side chain increased lipophilicity compared to the parent compound, allowing blood–brain barrier permeability and GABA transporter 1 (GAT-1) selectivity. The experimental log P of tiagabine is 2.6. Analogues of tiagabine include CI-966, NNC-711, and SKF-89976A, among others.
Isoergine, also known as isolysergic acid amide (iso-LSA or iso-LA-819), isolysergamide, or erginine, is a serotonergic psychedelic of the ergoline and lysergamide families related to ergine (lysergic acid amide; LSA) and lysergic acid diethylamide (LSD). It is the epimer of ergine inverted at the 8 position. Along with ergine and other ergolines, isoergine occurs naturally in morning glories. It is thought to be primarily responsible for the hallucinogenic effects of morning glory seeds.
Sources: en.wikipedia.org
The Five Guys menu focuses on hamburgers offered with Kraft American cheese or applewood-smoked bacon and kosher style hot dogs (Hebrew National all-beef franks), as well as grilled cheese, BLT and vegetable sandwiches. Five Guys uses buns that are sweeter and "eggier" than normal buns. The hamburgers come in two sizes: regular (two patties) and little (one patty). Customers may select from 15 toppings at no charge. Fresh-cut french fries are the sole side item, available salted only in "Five Guys style" or seasoned "Cajun style". Conventionally, Five Guys employees are directed to give customers an extra scoop of fries for free when they order. The rationale was to persuade the customer that they were getting a good deal by giving them more fries than they'd paid for. However, the extras were already accounted for in the initial pricing. Complimentary roasted in-shell peanuts are offered for on-site consumption at most locations, with signage alerting potential customers who may have a peanut allergy; for these allergen reasons, customers are not allowed to take peanuts off-site.
6 May 1986 – USS Ray, USS Archerfish and USS Hawkbill meet and surface together at the Geographic North Pole. First three-submarine surfacing at the Pole. 19 May 1987 – HMS Superb joined USS Billfish and USS Sea Devil at the North Pole. March 2007 – USS Alexandria participated in the Joint US Navy/Royal Navy Ice Exercise 2007 (ICEX-2007) in the Arctic Ocean with the Trafalgar-class submarine HMS Tireless. March 2009 – USS Annapolis took part in Ice Exercise 2009 to test submarine operability and war-fighting capability in Arctic conditions.
== Further reading == Li, Qing. "日本人作家の見た中国 : 『李香蘭 私の半生』と『大地の子』から" [The Image of China from the viewpoint of Japanese writers (the sub-title refers to Fragrant Orchid and Child of the Earth)]. Journal of Matsusaka University (in Japanese) (10). Matsusaka University: 39–50. - Profile at CiNii. The other series documented is Child of the Earth.
Sources: en.wikipedia.org
=== H: Diseases of the eye, adnexa, ear, and mastoid process === (H04.6) Lacrimal fistula (H05.81) Carotid cavernous fistula (H70.1) Mastoid fistula Craniosinus fistula: between the intracranial space and a paranasal sinus (H83.1) Labyrinthine fistula Perilymph fistula: tear between the membranes between the middle and inner ears Preauricular fistula Preauricular fistula: usually on the top of the cristae helicis of the ears
=== Calcium oxalate production === Chocolate has oxalic acid, which reacts with the calcium in the milk producing calcium oxalate, thus preventing the calcium from being absorbed in the intestine. However, it is present in small enough amounts that the effect on calcium absorption is negligible (2–3%). As chocolate contains relatively small amounts of oxalate, it is unclear to what extent chocolate consumption affects healthy people with calcium-rich diets. In a 2008 study, participants who consumed one or more servings of chocolate on a daily basis had lower bone density and strength than those participants who ate a serving of chocolate six times a week or less. Researchers believe this may be due to oxalate inhibiting calcium absorption – but it could also be due to sugar content in chocolate, which may increase calcium excretion. It is clear, however, that consuming foods high in oxalate – and in turn their effect on calcium absorption – is a more significant concern for people with oxalate kidney stones, which occur when there is too much oxalate in the urine. These people especially should reduce their oxalate intake and increase their calcium intake. However, the high magnesium content in chocolate is likely to reduce the risk of stone formation, because like citrate, magnesium is also an inhibitor of urinary crystal formation.
In Canada, cream soda is mostly pink with a taste reminiscent of grenadine, although clear versions can be found in Quebec and Atlantic Canada. Some brands, such as Fanta, market clear cream soda nationwide. Many brands have a long-lasting, foamy head. Brands include:
=== Treating vitamin deficiency in newborns === Vitamin K1 is given as an injection to newborns to prevent vitamin K deficiency bleeding. The blood clotting factors of newborn babies are roughly 30–60% that of adult values; this appears to be a consequence of poor transfer of the vitamin across the placenta, and thus low fetal plasma vitamin K. Occurrence of vitamin K deficiency bleeding in the first week of the infant's life is estimated at between 1 in 60 and 1 in 250. Human milk contains 0.85–9.2 μg/L (median 2.5 μg/L) of vitamin K1, while infant formula is formulated in range of 24–175 μg/L. Late onset bleeding, with onset 2 to 12 weeks after birth, can be a consequence of exclusive breastfeeding, especially if there was no preventive treatment. Late onset prevalence reported at 35 cases per 100,000 live births in infants who had not received prophylaxis at or shortly after birth. Vitamin K deficiency bleeding occurs more frequently in the Asian population compared to the Caucasian population. Bleeding in infants due to vitamin K deficiency can be severe, leading to hospitalization, brain damage, and death. Intramuscular injection, typically given shortly after birth, is more effective in preventing vitamin K deficiency bleeding than oral administration, which calls for weekly dosing up to three months of age.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.